J.BrassatD.DrooganA
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
The D-Retro-Inverso modification ensures the peptide maintains its binding affinity while resisting proteolytic degradation, allowing extended therapeutic activity for senescent cell targeting in complex tissue environments
The method of any one of embodiments 1-72, wherein the composition further comprises an antimicrobial agent
In severe cases, cognitive difficulties like confusion or dementia-like symptoms may develop
Eyedropper can be cleaned and reused for other applications